72 results
Page 2 of 4
8-K
EX-99.1
ynjj o67dnugiamd
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.2
i5e080kxkn76 x3mm
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.4
b4f7 4nomn4wc3fb
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
os64x6d x8
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.2
3u1ryw 1gi8or
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
5u8w1bddcfz lsjq8i
25 May 23
Other Events
6:08am
8-K
EX-99.1
8ij2qc
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
2z7cxg5gy bfss
8 Aug 22
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
4:30pm
8-K
EX-10.1
m6v0f7f1owdnnr
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.2
vyd0kncxnorp3m3xol4r
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.1
eqle3a a9nd
7 Jun 22
Other Events
4:06pm
8-K
EX-99.1
ff5cu55a2f4 5nlwn
7 Apr 22
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
5:27pm
8-K
EX-99.1
x8zyyd
10 Jan 22
Regulation FD Disclosure
6:40am